Sign inJoin waitlistJoin the waitlist

Lindsey Beffa

Associate Residency Program Director, Subspecialty Care for Women's Health · Cleveland Clinic Foundation

Credentials: · · · · · · ·

History

Subspecialty Care for Women's Health · Cleveland Clinic Foundation
Present
Cleveland Clinic Foundation
Present

Women and Infants Hosp. of Rhode Island/Brown University
2016–2019
Obstetrics and Gynecology
University of Missouri Hospital and Clinics
2011–2015
Univ of Missouri, Columbia Sch of Med
2007–2011
University of Missouri - Columbia
2003–2007

Research

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
New England Journal of Medicine · 2023 · 633 citations
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Nature Medicine · 2025 · 59 citations
The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes
Scientific Reports · 2020 · 28 citations

CM
Cara Mathews
4 papers
Katina Robison
4 papers
PD
Paul DiSilvestro
4 papers
Amy Brown
3 papers
AS
Ashley Stuckey
3 papers
AV
Ashley Valenzuela
3 papers · 3 as a fellow
Disha Dalela
3 papers · 3 as a resident
Elizabeth Lokich
3 papers
EH
Erin Hofstatter
3 papers · 2 as a resident
Jessica Haddad
3 papers · 3 as a resident
Leslie Bradford
3 papers
Maris Toland
3 papers · 3 as a resident

Clinical trials

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Site PI · Recruiting
NRG Oncology
2020–2047
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
Sub-investigator · Recruiting · Phase 2
Frantz Viral Therapeutics, LLC
2023–2027